TIDMIMM

Immupharma PLC

30 September 2021

REACH| 30 SEPTEMBER 2021

ImmuPharma PLC

("ImmuPharma", the "Company" or the "Group")

PROF. SYLVIANE MULLER AWARDED PRESTIGIOUS

'LEGION D'HONNEUR'

ImmuPharma PLC (LSE:IMM; Euronext Growth Brussels: ALIMM), the specialist drug discovery and development company, is delighted to announce that Prof. Sylviane Muller, inventor of Lupuzor(TM) and P140 technology and a key collaboration partner, has been awarded the highly prestigious Legion d'honneur Award.

The ' Remise des insignes d'officier de la Légion d'honneur' was presented to Prof. Muller at an

awards ceremony yesterday evening at l'Institut de Science et d'Ingénierie Supramoléculaires (ISIS) in Strasbourg.

The 'Legion of Honor' is the highest French decoration and one of the most famous in the world. For two centuries, being established in 1802 by Napoleon Bonaparte, it has been retained by all later French governments and presented on behalf of the Head of State to reward the most deserving citizens in all fields of activity.

Commenting on this award, Tim McCarthy, CEO and Chairman of ImmuPharma, said:

" On behalf of the Board and the whole team at ImmuPharma, we congratulate Prof. Muller on this highly prestigious award, which is highly deserving, in recognition of her many years of work and commitment to understanding the complexities of the human immune system. We are hugely honoured to be working in partnership with Prof. Muller on Lupuzor(TM) and the P140 platform, in which her passion and drive and collaborative approach has been an invaluable contribution to our clinical team, as we move closer to offering therapeutic drugs, initially in lupus, which will be of enormous benefit to patients."

End

 
 
   For further information please contact: 
    ImmuPharma PLC ( www.immupharma.com ) 
     Tim McCarthy, Chief Executive Officer & 
     Chairman                                      + 44 (0) 207 152 4080 
 
    Lisa Baderoon, Head of Investor Relations 
     & Non-Executive Director                      + 44 (0) 7721 413496 
    SPARK Advisory Partners Limited (NOMAD) 
     Neil Baldwin                                  +44 (0) 203 36 8 3550 
 
     Stanford Capital Partners (Joint Broker) 
     Patrick Claridge                               +44 20 3650 3650 
     John Howes 
     Bob Pountney 
 
     SI Capital (Joint Broker) 
     Nick Emerson                                   +44 (0) 1483 413500 
    4Reliance (Euronext Growth Listing Sponsor)    +32 (0) 2 747 02 60 
     Jean-Charles Snoy 
 
     Degroof Petercam (Liquidity Provider)          +32 (0) 2 287 95 34 
     Erik De Clippel 
 
     Backstage Communication 
     Olivier Duquaine                               +32 (0) 477 504 784 
     Gunther De Backer                              +32 (0) 475 903 909 
 

Notes to Editors

About ImmuPharma PLC

ImmuPharma PLC (LSE AIM: IMM - Euronext Growth: ALIMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases, metabolic diseases, anti-infectives and cancer. The lead program, Lupuzor(TM), is a first-in class autophagy immunomodulator which is in Phase 3 for the treatment of lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action. ImmuPharma and Avion Pharmaceuticals signed on 28 November 2019, an exclusive licence and development agreement and trademark agreement for Lupuzor(TM) to fund a new international Phase 3 trial for Lupuzor(TM) and commercialise in the US.

For additional information about ImmuPharma please visit www.immupharma.co.uk

ImmuPharma's LEI (Legal Entity Identifier) code: 213800VZKGHXC7VUS895.

About Legion d'honneur

The Legion of Honor is the highest French decoration and one of the most famous in the world. For two centuries, being established in 1802 by Napoleon Bonaparte, it has been retained by all later French governments and presented on behalf of the Head of State to reward the most deserving citizens in all fields of activity.

The order's motto is Honneur et Patrie ("Honour and Fatherland"), and its seat is the Palais de la Légion d'Honneur next to the Musée d'Orsay , on the left bank of the Seine in Paris .

The order is divided into five degrees of increasing distinction: Chevalier ( Knight ), Officier (Officer), Commandeur ( Commander ), Grand officier (Grand Officer), and Grand-croix ( Grand Cross ). For more information go to: www.legiondhonneur.fr/en

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word "Reach" in the source column of the News Explorer pages of London Stock Exchange's website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRASDUSMSEFSESU

(END) Dow Jones Newswires

September 30, 2021 02:14 ET (06:14 GMT)

Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Oct 2021 a Nov 2021 Haga Click aquí para más Gráficas Immupharma.
Immupharma (LSE:IMM)
Gráfica de Acción Histórica
De Nov 2020 a Nov 2021 Haga Click aquí para más Gráficas Immupharma.